Sunshine Biopharma Inc. (SBFM): Nasdaq/NYSE listing notice — Sunshine Biopharma receives Nasdaq deficiency notice for bid price below $1.00

Sunshine Biopharma Inc.

Nasdaq notified SBFM on March 24, 2023, of bid price non-compliance under Rule 5550(a)(2).
Closing bid price below $1.00 for 30 consecutive trading days triggered the deficiency.
Company has 180 calendar days until September 20, 2023, to regain compliance.
To cure, bid price must close at or above $1.00 for at least 10 consecutive business days.
If not cured, SBFM may qualify for an additional 180-day period if other listing standards are met.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Sunshine Biopharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 24, 2023, Sunshine Biopharma, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immed

View on SEC.gov

Browse all listing & compliance notices →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-001754

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.